{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\", docket_id = \"FDA-2010-N-0621\" and posted_year = 2011 sorted by posted_date descending", "rows": [["FDA-2010-N-0621-0544", "FDA", "FDA-2010-N-0621", "Decision of the Commissioner re Proposal to Withdraw Approval for the Breast Cancer Indication for Bevacizumab (Avastin) November 18, 2011 - Commissioner's Decision", "Other", "Commissioners Decision", "2011-11-21T05:00:00Z", 2011, 11, "2011-11-21T05:00:00Z", null, "2013-07-28T00:08:47Z", null, 0, 0, "0900006480f707b0"], ["FDA-2010-N-0621-0538", "FDA", "FDA-2010-N-0621", "Proposal to Withdraw Approval for the Breast Cancer Indication for Bevacizumab (Avastin) Public Hearing June 29, 2011 - Transcript", "Other", "Transcript(s)", "2011-11-03T04:00:00Z", 2011, 11, "2011-11-03T04:00:00Z", null, "2011-11-03T20:58:33Z", null, 0, 0, "0900006480f659ad"], ["FDA-2010-N-0621-0537", "FDA", "FDA-2010-N-0621", "Proposal to Withdraw Approval for the Breast Cancer Indication for Bevacizumab (Avastin) Public Hearing, June 28, 2011 - Transcript", "Other", "Transcript(s)", "2011-11-03T04:00:00Z", 2011, 11, "2011-11-03T04:00:00Z", null, "2011-11-03T20:49:56Z", null, 0, 0, "0900006480f65986"], ["FDA-2010-N-0621-0535", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Michael Labson, September 27, 2011, Email Message - Electronic Letter", "Other", "Electronic Letter", "2011-10-20T04:00:00Z", 2011, 10, "2011-10-20T04:00:00Z", null, "2011-10-20T15:59:55Z", null, 0, 0, "0900006480f56f36"], ["FDA-2010-N-0621-0481", "FDA", "FDA-2010-N-0621", "Terrence D. Kalley, Freedom of Access to Medicines - Testimony", "Other", "Testimony", "2011-08-16T04:00:00Z", 2011, 8, "2011-08-16T04:00:00Z", null, "2011-08-16T21:41:13Z", null, 0, 0, "0900006480ed3aef"], ["FDA-2010-N-0621-0479", "FDA", "FDA-2010-N-0621", "FDA/CDER Post-Hearing Submission Supporting CDER\u2019s Proposal, August 4, 2011 - Background Material", "Other", "Background Material", "2011-08-04T04:00:00Z", 2011, 8, "2011-08-04T04:00:00Z", null, "2011-08-05T00:30:20Z", null, 0, 0, "0900006480ed6bdb"], ["FDA-2010-N-0621-0474", "FDA", "FDA-2010-N-0621", "Christi C. Turnage - Testimony", "Other", "Testimony", "2011-08-04T04:00:00Z", 2011, 8, "2011-08-04T04:00:00Z", null, "2013-08-11T03:16:27Z", null, 0, 0, "0900006480ed65d6"], ["FDA-2010-N-0621-0477", "FDA", "FDA-2010-N-0621", "FDA/CDER Counsel, re Avastin Submission Under Seal (Addendum), August 4, 2011 - Letter", "Other", "Electronic Letter", "2011-08-04T04:00:00Z", 2011, 8, "2011-08-04T04:00:00Z", null, "2011-08-04T21:07:05Z", null, 0, 0, "0900006480ed6bd4"], ["FDA-2010-N-0621-0467", "FDA", "FDA-2010-N-0621", "Elizabeth Cleary, RN - Testimony", "Other", "Testimony", "2011-08-04T04:00:00Z", 2011, 8, "2011-08-04T04:00:00Z", null, "2013-07-27T23:59:29Z", null, 0, 0, "0900006480ecd8ef"], ["FDA-2010-N-0621-0478", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) Post-Hearing Submission, August 4, 2011 - Background Material", "Other", "Background Material", "2011-08-04T04:00:00Z", 2011, 8, "2011-08-04T04:00:00Z", null, "2013-07-28T00:00:16Z", null, 0, 0, "0900006480ed7758"], ["FDA-2010-N-0621-0463", "FDA", "FDA-2010-N-0621", "Genentech, Inc., (Covington & Burling LLP), July 25, 2011 - Request for Extension", "Other", "Request for Extension of Time in which to file a document", "2011-08-03T04:00:00Z", 2011, 8, "2011-08-03T04:00:00Z", null, "2013-08-11T04:46:57Z", null, 0, 0, "0900006480eccda7"], ["FDA-2010-N-0621-0460", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Chief Counsel to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun) re Avastin Submission Under Seal, August 3, 2011 - Letter", "Other", "Electronic Letter", "2011-08-03T04:00:00Z", 2011, 8, "2011-08-03T04:00:00Z", null, "2011-08-03T23:37:00Z", null, 0, 0, "0900006480ed6192"], ["FDA-2010-N-0621-0459", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, August 3, 2011 - Letter", "Other", "Letter(s)", "2011-08-03T04:00:00Z", 2011, 8, "2011-08-03T04:00:00Z", null, "2011-08-03T23:28:29Z", null, 0, 0, "0900006480ed6190"], ["FDA-2010-N-0621-0458", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Chief Counsel to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), August 2, 2011 - Letter", "Other", "Letter(s)", "2011-08-02T04:00:00Z", 2011, 8, "2011-08-02T04:00:00Z", null, "2013-08-11T04:47:02Z", null, 0, 0, "0900006480ed413a"], ["FDA-2010-N-0621-0457", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Chief Counsel to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), July 29, 2011 - Letter", "Other", "Letter(s)", "2011-08-01T04:00:00Z", 2011, 8, "2011-08-01T04:00:00Z", null, "2013-07-27T23:59:42Z", null, 0, 0, "0900006480ed1415"], ["FDA-2010-N-0621-0456", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, July 26, 2011 - Letter", "Other", "Letter(s)", "2011-07-27T04:00:00Z", 2011, 7, "2011-07-27T04:00:00Z", null, "2011-07-27T21:57:58Z", null, 0, 0, "0900006480ece10c"], ["FDA-2010-N-0621-0453", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to Charoltte, Nortrh Carolina Constutient (Senator Richard Burr) - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:37:47Z", null, 0, 0, "0900006480ec1375"], ["FDA-2010-N-0621-0450", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable David Vitter - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:42:30Z", null, 0, 0, "0900006480ec1360"], ["FDA-2010-N-0621-0444", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Rodney P. Frelinghuysen - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:22:29Z", null, 0, 0, "0900006480ec1302"], ["FDA-2010-N-0621-0447", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable John Barrasso, M.D. - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:44:35Z", null, 0, 0, "0900006480ec1321"], ["FDA-2010-N-0621-0448", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Roger F. Wicker - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:44:00Z", null, 0, 0, "0900006480ec133a"], ["FDA-2010-N-0621-0451", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Thad Cochran - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:41:59Z", null, 0, 0, "0900006480ec1366"], ["FDA-2010-N-0621-0443", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Carl Levin - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:20:15Z", null, 0, 0, "0900006480ec1300"], ["FDA-2010-N-0621-0449", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Jack Kingston - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:43:12Z", null, 0, 0, "0900006480ec133f"], ["FDA-2010-N-0621-0442", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Gary C. Peters - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:20:41Z", null, 0, 0, "0900006480ec12fe"], ["FDA-2010-N-0621-0445", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Joseph I Lieberman - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:45:44Z", null, 0, 0, "0900006480ec131d"], ["FDA-2010-N-0621-0454", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Daniel Webster - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:39:41Z", null, 0, 0, "0900006480ec1398"], ["FDA-2010-N-0621-0446", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to the Honorable Ileana Lehtinen - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:45:08Z", null, 0, 0, "0900006480ec131f"], ["FDA-2010-N-0621-0452", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation to Madison, Alabama Constutient (Senator Jeff Sessions) - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:41:25Z", null, 0, 0, "0900006480ec136e"], ["FDA-2010-N-0621-0441", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Legislation Response to the Honorable Gregg Harper - Letter", "Other", "Letter(s)", "2011-07-21T04:00:00Z", 2011, 7, "2011-07-21T04:00:00Z", null, "2011-07-21T15:21:09Z", null, 0, 0, "0900006480ec12fc"], ["FDA-2010-N-0621-0429", "FDA", "FDA-2010-N-0621", "Genentech - Transcript", "Other", "Transcript(s)", "2011-07-11T04:00:00Z", 2011, 7, "2011-07-11T04:00:00Z", null, "2013-07-27T23:57:25Z", null, 0, 0, "0900006480eb83a4"], ["FDA-2010-N-0621-0421", "FDA", "FDA-2010-N-0621", "Voting Results from Advisory Committee Members at Hearing on June 29, 2011 - List", "Other", "List (LST)", "2011-07-05T04:00:00Z", 2011, 7, "2011-07-05T04:00:00Z", null, "2011-07-05T16:56:42Z", null, 0, 0, "0900006480eb9011"], ["FDA-2010-N-0621-0420", "FDA", "FDA-2010-N-0621", "Dr. Midthun Response to Dr. Brown-Beasley, July 5, 2011 - E-Letter", "Other", "Electronic Letter", "2011-07-05T04:00:00Z", 2011, 7, "2011-07-05T04:00:00Z", null, "2011-07-05T16:46:15Z", null, 0, 0, "0900006480eb900f"], ["FDA-2010-N-0621-0419", "FDA", "FDA-2010-N-0621", "Dr. Midthun Response to Patricia Howard, June 30, 2011 - E-Letter", "Other", "Electronic Letter", "2011-07-05T04:00:00Z", 2011, 7, "2011-07-05T04:00:00Z", null, "2011-07-05T16:43:01Z", null, 0, 0, "0900006480eb8fe8"], ["FDA-2010-N-0621-0360", "FDA", "FDA-2010-N-0621", "Avastin - \"Referenced Slides\" -  [Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing]", "Other", "Petition(s)", "2011-06-30T04:00:00Z", 2011, 6, null, null, "2011-06-30T19:02:57Z", null, 0, 0, "0900006480eb76b2"], ["FDA-2010-N-0621-0359", "FDA", "FDA-2010-N-0621", "Avastin Final Presentation - \"Administrative Hearing Proposal to Withdraw Accelerated Approval of Avastin for 1st Line Metastatic Breast Cancer\" -  [Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing]", "Other", "Presentation", "2011-06-30T04:00:00Z", 2011, 6, "2011-06-30T04:00:00Z", null, "2011-06-30T18:55:45Z", null, 0, 0, "0900006480eb768e"], ["FDA-2010-N-0621-0369", "FDA", "FDA-2010-N-0621", "FDA/OC Memo to the Division of Dockets Management, June 30, 2011 - Memorandum", "Other", "Memorandum", "2011-06-30T04:00:00Z", 2011, 6, "2011-06-30T04:00:00Z", null, "2013-07-27T23:57:20Z", null, 0, 0, "0900006480eb7795"], ["FDA-2010-N-0621-0343", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, June 27, 2011 - Letter", "Other", "Letter(s)", "2011-06-29T04:00:00Z", 2011, 6, "2011-06-29T04:00:00Z", null, "2011-06-29T19:48:31Z", null, 0, 0, "0900006480eb67f8"], ["FDA-2010-N-0621-0342", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), June 27, 2011 - Letter", "Other", "Letter(s)", "2011-06-29T04:00:00Z", 2011, 6, "2011-06-29T04:00:00Z", null, "2011-06-29T19:45:12Z", null, 0, 0, "0900006480eb67f6"], ["FDA-2010-N-0621-0308", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), June 24, 2011 - Letter", "Other", "Letter(s)", "2011-06-24T04:00:00Z", 2011, 6, "2011-06-24T04:00:00Z", null, "2011-06-24T20:00:09Z", null, 0, 0, "0900006480eb35cc"], ["FDA-2010-N-0621-0298", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), June 23, 2011 - Letter", "Other", "Letter(s)", "2011-06-23T04:00:00Z", 2011, 6, null, null, "2011-06-23T19:13:53Z", null, 0, 0, "0900006480ead27d"], ["FDA-2010-N-0621-0299", "FDA", "FDA-2010-N-0621", "FDA Commissioner of Food and Drugs re Advisory Committee Quorum - Memo to File", "Other", "Memorandum", "2011-06-23T04:00:00Z", 2011, 6, "2011-06-23T04:00:00Z", null, "2011-06-23T22:42:32Z", null, 0, 0, "0900006480ead3dc"], ["FDA-2010-N-0621-0195", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, June 20, 2011 - Letter", "Other", "Letter(s)", "2011-06-21T04:00:00Z", 2011, 6, "2011-06-21T04:00:00Z", null, "2011-06-21T12:31:38Z", null, 0, 0, "0900006480e69ad5"], ["FDA-2010-N-0621-0194", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), June 17, 2011 - Letter", "Other", "Letter(s)", "2011-06-17T04:00:00Z", 2011, 6, "2011-06-17T04:00:00Z", null, "2011-06-17T21:13:03Z", null, 0, 0, "0900006480e52568"], ["FDA-2010-N-0621-0193", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) to the Presiding Officer (Karen Midthun, M.D.), June 13, 2011 - Letter", "Other", "Letter(s)", "2011-06-16T04:00:00Z", 2011, 6, "2011-06-16T04:00:00Z", null, "2013-08-11T03:15:21Z", null, 0, 0, "0900006480e4f82f"], ["FDA-2010-N-0621-0192", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), June 3, 2011, re Presenters and Curricala Vitae/Biographies - Letter", "Other", "Letter(s)", "2011-06-16T04:00:00Z", 2011, 6, "2011-06-16T04:00:00Z", null, "2011-06-20T14:09:52Z", null, 0, 0, "0900006480e51e22"], ["FDA-2010-N-0621-0191", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), June 15, 2011 - Letter", "Other", "Letter(s)", "2011-06-15T04:00:00Z", 2011, 6, "2011-06-15T04:00:00Z", null, "2011-06-16T00:38:59Z", null, 0, 0, "0900006480e500ff"], ["FDA-2010-N-0621-0161", "FDA", "FDA-2010-N-0621", "Test FDMS 3.5 release w/added public submission no submitter's info", "Supporting & Related Material", null, "2011-06-14T00:00:00Z", 2011, 6, null, null, "2024-11-07T22:32:19Z", null, 0, 1, "0900006480e50287"], ["FDA-2010-N-0621-0155", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), May 27, 2011, re Presenters and Curricala Vitae/Biographies - Letter", "Other", "LET-Letter", "2011-05-31T04:00:00Z", 2011, 5, "2011-05-31T04:00:00Z", null, "2011-06-14T20:59:13Z", null, 0, 0, "0900006480e34316"], ["FDA-2010-N-0621-0156", "FDA", "FDA-2010-N-0621", "Appendix 15 Substitution of the \"Statistical Review and Evaluation\u201d document in Appendix 15 (CDER\u2019s Review of sBLA STN125085\\191, AVADO) to the CDER May 13, 2011 submission (ref FDA-2010-N-0621-0145.15)", "Supporting & Related Material", "RPT-Report (Supporting and Related Material)", "2011-05-31T04:00:00Z", 2011, 5, null, null, "2011-06-21T15:14:52Z", null, 0, 0, "0900006480e3711a"], ["FDA-2010-N-0621-0154", "FDA", "FDA-2010-N-0621", "Genentech, Inc., (Covington & Burling LLP) to Karen Midthun, M.D., Presiding Officer, re Witness List and Curriculum Vitae - Letter", "Other", "LET-Letter", "2011-05-27T04:00:00Z", 2011, 5, "2011-05-27T04:00:00Z", null, "2013-07-27T23:54:24Z", null, 0, 0, "0900006480e34356"], ["FDA-2010-N-0621-0152", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, May 25, 2011 - Letter", "Other", "LET-Letter", "2011-05-26T04:00:00Z", 2011, 5, "2011-05-26T04:00:00Z", null, "2013-07-27T23:54:13Z", null, 0, 0, "0900006480e32f1a"], ["FDA-2010-N-0621-0150", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) to the Presiding Officer (Karen Midthun, M.D.), May 18, 2011 - Letter", "Other", "LET-Letter", "2011-05-26T04:00:00Z", 2011, 5, "2011-05-26T04:00:00Z", null, "2013-07-27T23:53:27Z", null, 0, 0, "0900006480d52ad6"], ["FDA-2010-N-0621-0151", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) to the Presiding Officer (Karen Midthun, M.D.), May 20, 2011 - Letter", "Other", "LET-Letter", "2011-05-26T04:00:00Z", 2011, 5, "2011-05-26T04:00:00Z", null, "2013-08-11T04:45:57Z", null, 0, 0, "0900006480dd3015"], ["FDA-2010-N-0621-0148", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Chief Counsel to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), May 17, 2011 - Letter", "Other", "LET-Letter", "2011-05-17T04:00:00Z", 2011, 5, "2011-05-17T04:00:00Z", null, "2013-08-11T01:41:41Z", null, 0, 0, "0900006480d1081a"], ["FDA-2010-N-0621-0147", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) to the Presiding Officer (Karen Midthun, M.D.), May 16, 2011 - Letter", "Other", "LET-Letter", "2011-05-16T04:00:00Z", 2011, 5, "2011-05-16T04:00:00Z", null, "2013-07-27T23:53:07Z", null, 0, 0, "0900006480cd80e9"], ["FDA-2010-N-0621-0146", "FDA", "FDA-2010-N-0621", "Genentech, Inc., (Covington & Burling LLP) - Pre-Hearing Summary of Evidence and Arguments", "Other", "AR-Argument", "2011-05-16T04:00:00Z", 2011, 5, "2011-05-16T04:00:00Z", null, "2013-07-27T23:53:02Z", null, 0, 0, "0900006480c7a3b5"], ["FDA-2010-N-0621-0145", "FDA", "FDA-2010-N-0621", "Appendices List (1-35) - [FDA/CDER, Summary of Arguments Supporting CDER\u2019s Proposal to Withdraw Approval of Avastin\u2019s Indication for the Treatment of Metastatic Breast Cancer - Summary of Agruments]", "Supporting & Related Material", "Reference (internal unless indicated)", "2011-05-16T04:00:00Z", 2011, 5, null, null, "2018-09-10T22:40:02Z", null, 0, 0, "0900006480c7a7c3"], ["FDA-2010-N-0621-0143", "FDA", "FDA-2010-N-0621", "Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing", "Notice", "NH-Notice of Hearing", "2011-05-11T04:00:00Z", 2011, 5, "2011-05-11T04:00:00Z", "2011-08-05T03:59:59Z", "2011-08-03T23:59:42Z", "2011-11539", 0, 0, "0900006480c6c051"], ["FDA-2010-N-0621-0142", "FDA", "FDA-2010-N-0621", "Dr. Midthun Response to Patricia Howard, May 6, 2011 - Letter", "Other", "LET-Letter", "2011-05-09T04:00:00Z", 2011, 5, "2011-05-09T04:00:00Z", null, "2011-05-09T20:43:44Z", null, 0, 0, "0900006480c4386f"], ["FDA-2010-N-0621-0140", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, May 6, 2011 - Letter", "Other", "LET-Letter", "2011-05-09T04:00:00Z", 2011, 5, "2011-05-09T04:00:00Z", null, "2011-05-09T20:27:46Z", null, 0, 0, "0900006480c4386d"], ["FDA-2010-N-0621-0141", "FDA", "FDA-2010-N-0621", "Dr. Midthun to the Oncologic Drugs Advisory Committee Members, May 6, 2011 - Letter", "Other", "LET-Letter", "2011-05-09T04:00:00Z", 2011, 5, "2011-05-09T04:00:00Z", null, "2011-05-18T15:45:04Z", null, 0, 0, "0900006480c4386e"], ["FDA-2010-N-0621-0138", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, May 2, 2011 - Letter", "Other", "LET-Letter", "2011-05-04T04:00:00Z", 2011, 5, "2011-05-04T04:00:00Z", null, "2011-05-04T18:36:48Z", null, 0, 0, "0900006480c3f070"], ["FDA-2010-N-0621-0134", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) Response to FDA/CDER, April 8, 2011 - Letter", "Other", "LET-Letter", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-08-11T04:45:02Z", null, 0, 0, "0900006480c1f843"], ["FDA-2010-N-0621-0135", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) Response to FDA/CDER, April 13, 2011 - Letter", "Other", "LET-Letter", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-07-27T23:50:15Z", null, 0, 0, "0900006480c2a4a7"], ["FDA-2010-N-0621-0132", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) to FDA/CDER - re Joint Statement of Undisputed Facts and Select Issues in Dispute of the FDA Center for Drug Evaluation and Research and Genentech, Inc. - Letter", "Other", "LET-Letter", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-07-27T23:49:39Z", null, 0, 0, "0900006480c1ea22"], ["FDA-2010-N-0621-0136", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, April 18, 2011 - Letter", "Other", "LET-Letter", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-07-27T23:50:44Z", null, 0, 0, "0900006480c3020b"], ["FDA-2010-N-0621-0133", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) and FDA/CDER Joint Response to the Presiding Officer Dr. Karen Midthun, April 7, 2011 - Letter", "Other", "LET-Letter", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-08-11T03:14:06Z", null, 0, 0, "0900006480c1ea2b"], ["FDA-2010-N-0621-0130", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) Response to FDA/CDER, April 5, 2011 - Letter", "Other", "Letter(s)", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-08-11T01:40:57Z", null, 0, 0, "0900006480c1e3c2"], ["FDA-2010-N-0621-0131", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) - Electronic Letter", "Other", "ELET-Electronic Letter", "2011-04-19T04:00:00Z", 2011, 4, "2011-04-19T04:00:00Z", null, "2013-08-11T03:14:06Z", null, 0, 0, "0900006480c1ea1e"], ["FDA-2010-N-0621-0129", "FDA", "FDA-2010-N-0621", "FDA Office of the Ombudsman Repsonse to Covington & Burling LLP, April 13, 2011 - Letter", "Other", "LET-Letter", "2011-04-14T04:00:00Z", 2011, 4, "2011-04-14T04:00:00Z", null, "2011-06-14T20:15:43Z", null, 0, 0, "0900006480c2cb22"], ["FDA-2010-N-0621-0128", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), April 11, 2011 - Letter", "Other", "LET-Letter", "2011-04-12T04:00:00Z", 2011, 4, "2011-04-12T04:00:00Z", null, "2013-07-27T23:49:55Z", null, 0, 0, "0900006480c22ccf"], ["FDA-2010-N-0621-0127", "FDA", "FDA-2010-N-0621", "Center for Drug Evaluation and Research -  \"CDER's Statement of Questions Presented\" - Reply Statement", "Other", "S-Reply Statement", "2011-04-12T04:00:00Z", 2011, 4, "2011-04-12T04:00:00Z", null, "2013-07-27T23:49:54Z", null, 0, 0, "0900006480c2225a"], ["FDA-2010-N-0621-0126", "FDA", "FDA-2010-N-0621", "FDA/OC (CDER) to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), April 7, 2011 - Letter", "Other", "LET-Letter", "2011-04-07T04:00:00Z", 2011, 4, "2011-04-07T04:00:00Z", null, "2013-07-27T23:49:40Z", null, 0, 0, "0900006480c1ed74"], ["FDA-2010-N-0621-0125", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Covington & Burling LLP(Michael Labson, Esq.), March 29, 2011 - Letter", "Other", "LET-Letter", "2011-04-01T04:00:00Z", 2011, 4, "2011-04-01T04:00:00Z", null, "2011-06-14T20:14:40Z", null, 0, 0, "0900006480c193dd"], ["FDA-2010-N-0621-0124", "FDA", "FDA-2010-N-0621", "Genentech, Inc. (Covington & Burling LLP) Response to FDA/CDER, March 10, 2011 - Letter", "Other", "Letter(s)", "2011-03-28T04:00:00Z", 2011, 3, "2010-12-16T05:00:00Z", null, "2013-08-11T03:13:50Z", null, 0, 0, "0900006480c0fbfc"], ["FDA-2010-N-0621-0122", "FDA", "FDA-2010-N-0621", "FDA/OC Office of Chief Counsel to the Presiding Officer, Center for Biologics Evaluation and Research (Dr. Midthun), March 22, 2011 - Letter", "Other", "LET-Letter", "2011-03-22T04:00:00Z", 2011, 3, "2011-03-22T04:00:00Z", null, "2011-06-14T20:14:16Z", null, 0, 0, "0900006480c0d522"], ["FDA-2010-N-0621-0121", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, March 10, 2011 - Letter", "Other", "Letter(s)", "2011-03-10T05:00:00Z", 2011, 3, "2011-03-10T05:00:00Z", null, "2013-08-11T03:13:35Z", null, 0, 0, "0900006480c05591"], ["FDA-2010-N-0621-0120", "FDA", "FDA-2010-N-0621", "FDA/OC and Genentech, Inc. (Covington & Burling) - Request for Extension of Time", "Other", "EXT-Request for Extension Comment Due Date", "2011-03-07T05:00:00Z", 2011, 3, "2011-03-07T05:00:00Z", null, "2013-08-11T04:44:32Z", null, 0, 0, "0900006480c02a24"], ["FDA-2010-N-0621-0118", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, March 3, 2011 - Letter", "Other", "Letter(s)", "2011-03-03T05:00:00Z", 2011, 3, "2011-03-03T05:00:00Z", null, "2011-06-21T12:35:05Z", null, 0, 0, "0900006480bfef5c"], ["FDA-2010-N-0621-0067", "FDA", "FDA-2010-N-0621", "Dr. Midthun to Counsel, February 23, 2011 - Letter", "Other", "LET-Letter", "2011-02-24T05:00:00Z", 2011, 2, "2011-02-24T05:00:00Z", null, "2011-03-03T21:55:11Z", null, 0, 0, "0900006480bf7086"], ["FDA-2010-N-0621-0052", "FDA", "FDA-2010-N-0621", "Attachment 9 - \"Clinical Review, Edvardas Kaminskas, Robert Lechleider, NDA22-065, Ixempra, ixabepilone\" - [Genentech, Inc. - Comment]  re FDA-2010-N-0621-0014", "Supporting & Related Material", "EREG-Electronic Regulation from Form Supporting and Related Material)", "2011-02-23T05:00:00Z", 2011, 2, null, null, "2012-03-24T19:36:28Z", null, 0, 0, "0900006480bcca25"], ["FDA-2010-N-0621-0015", "FDA", "FDA-2010-N-0621", "Attachment 1 - \"Prescribing Information, Avastin (Bevacizumab)\" - [Genentech, Inc. - Comment] re FDA-2010-N-0621-0014", "Supporting & Related Material", "EREG-Electronic Regulation from Form Supporting and Related Material)", "2011-01-24T05:00:00Z", 2011, 1, null, null, "2012-03-24T19:34:01Z", null, 0, 0, "0900006480bcc0f8"], ["FDA-2010-N-0621-0018", "FDA", "FDA-2010-N-0621", "Attachment 11 - \"CDER Medical Reviews\" - [Genentech, Inc. - Comment] re FDA-2010-N-0621-0014", "Supporting & Related Material", "EREG-Electronic Regulation from Form Supporting and Related Material)", "2011-01-24T05:00:00Z", 2011, 1, null, null, "2012-03-24T19:34:37Z", null, 0, 0, "0900006480bcca29"], ["FDA-2010-N-0621-0016", "FDA", "FDA-2010-N-0621", "Attachment 2 - \"Eastern Cooperative Oncology Group Memo dated August 23. 2005; Addendum #8, for E2100, A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer\" - [Genentech, Inc. - Comment] re FDA-2010-N-0621-0014", "Supporting & Related Material", "EREG-Electronic Regulation from Form Supporting and Related Material)", "2011-01-24T05:00:00Z", 2011, 1, null, null, "2012-03-24T19:33:25Z", null, 0, 0, "0900006480bcca10"], ["FDA-2010-N-0621-0017", "FDA", "FDA-2010-N-0621", "Attachment 4 - \"Briefing Book Oncology Drugs Advisory Committee Meeting, Avastin (Bevacizumab)\" - [Genentech, Inc. - Comment] re FDA-2010-N-0621-0014", "Supporting & Related Material", "EREG-Electronic Regulation from Form Supporting and Related Material)", "2011-01-24T05:00:00Z", 2011, 1, null, null, "2012-03-24T19:32:27Z", null, 0, 0, "0900006480bcca14"]], "truncated": false, "filtered_table_rows_count": 86, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 and \"posted_year\" = :p2 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-2010-N-0621", "p2": "2011"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011", "results": [{"value": "FDA", "label": "FDA", "count": 86, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2010-N-0621&posted_year=2011", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011", "results": [{"value": "Other", "label": "Other", "count": 77, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&document_type=Other", "selected": false}, {"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 8, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&document_type=Notice", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011", "results": [{"value": 2011, "label": 2011, "count": 86, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet=subtype"}, {"name": "posted_month", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet=posted_month"}, {"name": "withdrawn", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet=withdrawn"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2010-N-0621&posted_year=2011&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 418.99824800202623, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}